Pay in 4 interest-free payments of $5.72 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Disadvantages are poor stability, high production cost, and high production difficulty
Retatrutide activates three and reaches 28.7%
Check out these articles:
Zepbound and Hormonal Contraceptives: Drug Interaction Guide At a glance Drug pair / tirzepatide (Zepbound) + oral hormonal contraceptives Mechanism / delayed gastric emptying reduces oral contraceptive absorption Severity rating / moderate (per FDA labeling and Lexicomp) FDA guidance / use non-oral backup or barrier method for 4 weeks after initiation and each dose increase Affected formulations / combined oral contraceptives (COCs) and progestin-only pills Unaffected methods / patch, ring, implant, IUD, depot injection Peak gastric delay / strongest during first 1 to 4 weeks at any given dose Ethinyl estradiol Cmax reduction / ~55% after single tirzepatide dose in PK study Levonorgestrel AUC change / within bioequivalence limits but with delayed Tmax Clinical bottom line / unplanned pregnancy risk exists if no backup method is used during dose titration Why This Interaction Matters Tirzepatide is a dual GIP/GLP-1 receptor agonist approved for chronic weight management (Zepbound) and type 2 diabetes (Mounjaro)
